LEVAQUIN 250 MG
LEVOFLOXACIN : 250 MG · DIN 02236841 · JANSSEN INC
Health Canada status: CANCELLED POST MARKET
What is LEVAQUIN?
LEVAQUIN 250 MG contains LEVOFLOXACIN : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02236841, held by JANSSEN INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 27-Oct-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is LEVAQUIN used for?
LEVAQUIN® levofloxacin Tablets are indicated for the treatment of adults with bacterial infections caused by susceptible strains of the designated microorganisms in the infections listed below. Upper Respiratory Tract Acute sinusitis (mild to moderate) due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella (Branhamella) catarrhalis. Lower Respiratory Tract Acute bacterial exacerbations of chronic bronchitis (mild to moderate) due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella (Branhamella) catarrhalis. Community-acquired pneumonia (mild, moderate and severe infections) due to Staphylococcus aureus, Streptococcus pneumoniae (including penicillin-resistant strains), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella (Branhamella) catarrhalis, Chlamydia pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae. Nosocomial pneumonia due to methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae or Streptococcus pneumoniae. Skin and Skin Structure Uncomplicated skin and skin structure infections (mild to moderate) due to Staphylococcus aureus or Streptococcus pyogenes. Complicated skin and skin structure infections (mild to moderate), excluding burns, due to Enterococcus faecalis, methicillin-sensitive Staphylococcus aureus, Streptococcus pyogenes, Proteus mirabilis, or Streptococcus agalactiae. Urinary Tract Complicated urinary tract infections (mild to moderate) due to Enterococcus (Streptococcus) faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae or Staphylococcus saprophyticus. Acute pyelonephritis (mild to moderate) caused by Escherichia coli. Chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or Staphylococcus epidermidis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is LEVAQUIN called?
The same molecule, LEVOFLOXACIN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| LEVOACT | Latin | Saudi Arabia |
| Levofloxacin Krka | Latin | Sweden |
| Levofloxacin Viatris | Latin | Czechia, Sweden |
| Oftaquix | Latin | Saudi Arabia, Sweden |
| RAFLOX | Latin | Saudi Arabia |
| TAVANIC | Latin | Bahrain |
| Eradocin | Latin | Saudi Arabia |
| LEVANIX | Latin | Bahrain |
| LEVOFLOX | Latin | Bahrain |
| Levofloxacin Orion | Latin | Sweden |
| Levonic | Latin | Bahrain, Saudi Arabia |
| MATADOR | Latin | Bahrain |
| MAXITROL | Latin | Czechia |
| Nevotic | Latin | Saudi Arabia |
| SPERSADEX COMP. | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02236841 |
|---|---|
| Brand name | LEVAQUIN |
| Generic / active ingredient | LEVOFLOXACIN : 250 MG |
| Manufacturer | JANSSEN INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01MA12 LEVOFLOXACIN |
| AHFS class | 08:12.18 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 27-Oct-2014 |
| Original market date | 1997-11-28 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02236841 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2236841 |
| Brand name | LEVAQUIN |
| Active ingredient / INN | LEVOFLOXACIN : 250 MG |
| ATC code | J01MA12 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.18 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | JANSSEN INC |
How is it stored and handled?
null
How is it supplied?
null
Which pack is which?
| Strength on the label | 250 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | null |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is LEVOFLOXACIN in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01MA12 LEVOFLOXACIN. 16 of 54 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT LEVOFLOXACIN | 250 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315424 |
| ACT LEVOFLOXACIN | 500 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315432 |
| ACT LEVOFLOXACIN | 750 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02315440 |
| APO-LEVOFLOXACIN | 250 MG | TABLET | APOTEX INC | MARKETED | DIN 02284707 |
| APO-LEVOFLOXACIN | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02284715 |
| APO-LEVOFLOXACIN | 750 MG | TABLET | APOTEX INC | MARKETED | DIN 02325942 |
| JAMP LEVOFLOXACIN | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508443 |
| JAMP LEVOFLOXACIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508451 |
| JAMP LEVOFLOXACIN | 750 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02508478 |
| LEVOFLOXACIN | 500 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02415879 |
Who else supplies LEVOFLOXACIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LEVOFLOXACIN appears in 269 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does LEVOFLOXACIN cost around the world?
LEVOFLOXACIN is listed on 14 national price registers Nexara tracks, across 280 pack listings published on 12 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 50 | 59 | 01 Sep 2026 |
| South Africa | single exit price | 40 | 53 | 01 Sep 2026 |
| United States | acquisition | 4 | 27 | 03 Sep 2026 |
| Greece | producer price (ex-factory) | 25 | 25 | 03 Sep 2026 |
| Bahrain | retail (max) | 15 | 21 | 01 Sep 2026 |
| Romania | max producer price | 18 | 21 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 10 | 16 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 11 | 12 | 03 Sep 2026 |
| Czechia | max producer price (ex-factory) | 7 | 11 | 03 Sep 2026 |
| Luxembourg | reimbursement | 11 | 11 | 05 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 6 | 10 | 03 Sep 2026 |
| United Arab Emirates | public | 2 | 7 | 31 Aug 2026 |
| United Kingdom | hospital | 5 | 5 | 31 Aug 2026 |
| Iceland | max wholesale | 2 | 2 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.